Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.39 |
| ▸ | PDE4A | P27815 | 3/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21325097 | 0.84 | CNR2 (0.39) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13678313 | 0.79 | KMO (0.47) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18120363 | 0.79 | TRPV1 (0.45) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21350488 | 0.78 | PDE4B (0.36) | CNR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21325091 | 0.77 | RIPK1 (0.39) | CNR2CNR1SCN9A | |
| SCHEMBL879007 | 0.76 | DUT (0.47) | PDE4B | |
| SCHEMBL11951596 | 0.73 | ACACB (0.45) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19890462 | 0.72 | FFAR4 (0.40) | PDE4APDE4BPDE4CPDE4DSCN9A | |
| SCHEMBL17244896 | 0.72 | CNR2 (0.39) | CNR2CNR1SCN9A | |
| SCHEMBL21350486 | 0.71 | KAT6A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20210061767-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-03-04 | — | — | US | disclosed |
| US-10829457-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-11-10 | — | — | US | disclosed |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061767-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, DPYD, TYMP | CNR2 4414/4885PDE4A 2618/4885PDE4B 2599/4885 |
| US-10829457-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | CNR2 4414/4885PDE4A 2618/4885PDE4B 2599/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | CNR2 4414/4885PDE4A 2618/4885PDE4B 2599/4885 |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, DPYD, TYMP | CNR2 4414/4885PDE4A 2618/4885PDE4B 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.